We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+6.55%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$8.48B
AUM Growth
+$646M
(+8.3%)
Cap. Flow
-$773M
Cap. Flow
% of AUM
-9.12%
Top 10 Holdings %
Top 10 Hldgs %
50.85%
Holding
160
New
9
Increased
15
Reduced
10
Closed
78
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inspire Medical Systems
INSP
|
+$83.8M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$82.1M |
| 3 |
Pfizer
PFE
|
+$80.9M |
| 4 |
Genmab
GMAB
|
+$73.8M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$59.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$76.2M |
| 2 |
Revolution Medicines
RVMD
|
+$60.3M |
| 3 |
Phreesia
PHR
|
+$33.8M |
| 4 |
Ventas
VTR
|
+$27.4M |
| 5 |
Spyre Therapeutics
SYRE
|
+$23.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.65% |
| 2 | Consumer Discretionary | 0% |
| 3 | Consumer Staples | 0% |
| 4 | Financials | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Tyra Biosciences
TYRA
$1.91B
| $21M | 0.25% |
+549,000
| New | +$17.8M |
|
52
Foghorn Therapeutics
FHTX
$305M
| $21M | 0.25% |
4,394,367
+745,156
| +20% | +$4.09M |
|
|
DRUG
53
Bright Minds Biosciences
DRUG
$747M
| $20.7M | 0.24% |
+283,000
| New | +$22.8M |
|
54
Compass Therapeutics
CMPX
$369M
| $19.1M | 0.23% |
3,606,000
| – | – |
|
55
Monopar Therapeutics
MNPR
$744M
| $17.7M | 0.21% |
323,745
+153,187
| +90% | +$9.25M |
|
56
Kyverna Therapeutics
KYTX
$453M
| $17.3M | 0.2% |
2,000,000
| – | – |
|
|
SGP
57
SpyGlass Pharma
SGP
$661M
| $14.3M | 0.17% |
+550,000
| New | +$14.8M |
|
|
BBNX
58
Beta Bionics
BBNX
$770M
| $13.3M | 0.16% |
1,324,000
+385,692
| +41% | +$5.7M |
|
59
Taysha Gene Therapies
TSHA
$1.71B
| $12.2M | 0.14% |
2,722,165
| – | – |
|
60
The Oncology Institute
TOI
$535M
| $10.3M | 0.12% |
3,360,052
| – | – |
|
61
Cullinan Oncology
CGEM
$1.09B
| $5.49M | 0.06% |
386,169
| – | – |
|
62
Annexon
ANNX
$950M
| $3.23M | 0.04% |
583,913
| – | – |
|
63
Alector
ALEC
$167M
| $2.27M | 0.03% |
1,055,192
| – | – |
|
64
NewAmsterdam Pharma Warrant
NAMSW
| $1.86M | 0.02% |
92,787
| – | – |
|
65
Edwards Lifesciences
EW
$49.4B
| $1.1M | 0.01% |
13,702
| – | – |
|
66
BiomX
PHGE
$2.16M
| $493K | 0.01% |
131,272
+2
| +0% | +$9 |
|
|
MANE
67
Veradermics Inc
MANE
$4.65B
| $316K | ﹤0.01% |
+5,000
| New | +$252K |
|
68
Humana
HUM
$48B
| $159K | ﹤0.01% |
917
| – | – |
|
|
TOIIW
69
The Oncology Institute Warrant
TOIIW
$6.21M
| $54.8K | ﹤0.01% |
1,250,000
| – | – |
|
|
QSIAW
70
DELISTED
Quantum-Si Inc Warrant
QSIAW
| $36.2K | ﹤0.01% |
333,333
| – | – |
|
71
PMV Pharmaceuticals
PMVP
$71.5M
| $10.9K | ﹤0.01% |
8,790
| – | – |
|
72
Surrozen Inc Warrant
SRZNW
| $2.67K | ﹤0.01% |
166,666
| – | – |
|
73
Myriad Genetics
MYGN
$584M
| $2.27K | ﹤0.01% |
505
| – | – |
|
74
AbbVie
ABBV
$450B
| – | – |
-2,014
| Closed | -$460K |
|
75
Abeona Therapeutics
ABEO
$399M
| – | – |
-40,000
| Closed | -$211K |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q1 2026 Portfolio in Review
As of Q1 2026, Deerfield Management held 160 positions worth $8.48B, up 8.3% from $7.83B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Deerfield Management withdrew a net $773M in Q1 2026, closing 78 positions and reducing 10 holdings. Its most notable exit was Phreesia, an estimated $33.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
Against the trend, Deerfield Management opened a new position in Syndax Pharmaceuticals worth $88.3M.
- Deerfield Management's largest Q1 2026 buy was Syndax Pharmaceuticals: 3,779,900 shares worth $88.3M.
- Deerfield Management added most to Inspire Medical Systems in Q1 2026, an estimated $83.8M increase.
- Deerfield Management's biggest Q1 2026 reduction was Neurocrine Biosciences, cutting an estimated $76.2M.
- Deerfield Management fully exited Phreesia in Q1 2026, selling an estimated $33.8M.
- Deerfield Management's ten largest holdings make up 51% of its $8.48B portfolio in Q1 2026.
- Deerfield Management opened 9 new positions and closed 78 in Q1 2026.
- Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $8.48B.
Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.